Bank of New York Mellon’s Applied Therapeutics APLT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-253,575
| Closed | -$25.4K | – | 4199 |
|
|
2025
Q4 | $25.4K | Buy |
253,575
+174,157
| +219% | +$111K | ﹤0.01% | 4157 |
|
|
2025
Q3 | $48K | Hold |
79,418
| – | – | ﹤0.01% | 4132 |
|
|
2025
Q2 | $24.7K | Sell |
79,418
-237,037
| -75% | -$91.7K | ﹤0.01% | 4104 |
|
|
2025
Q1 | $155K | Buy |
316,455
+59,178
| +23% | +$34.8K | ﹤0.01% | 3942 |
|
|
2024
Q4 | $220K | Buy |
257,277
+10,831
| +4% | +$67.9K | ﹤0.01% | 3918 |
|
|
2024
Q3 | $2.09M | Sell |
246,446
-37,347
| -13% | -$220K | ﹤0.01% | 2717 |
|
|
2024
Q2 | $1.33M | Buy |
+283,793
| New | +$1.34M | ﹤0.01% | 3034 |
|
|
2024
Q1 | – | Sell |
-26,960
| Closed | -$90.3K | – | 4160 |
|
|
2023
Q4 | $90.3K | Buy |
+26,960
| New | +$67.1K | ﹤0.01% | 4103 |
|
|
2022
Q2 | – | Sell |
-70,458
| Closed | -$149K | – | 4583 |
|
|
2022
Q1 | $149K | Buy |
70,458
+2,062
| +3% | +$5.52K | ﹤0.01% | 4323 |
|
|
2021
Q4 | $612K | Buy |
68,396
+933
| +1% | +$12.3K | ﹤0.01% | 3667 |
|
|
2021
Q3 | $1.12M | Buy |
67,463
+8,955
| +15% | +$155K | ﹤0.01% | 3326 |
|
|
2021
Q2 | $1.22M | Sell |
58,508
-1,862
| -3% | -$35.2K | ﹤0.01% | 3291 |
|
|
2021
Q1 | $1.13M | Buy |
60,370
+1,698
| +3% | +$36.6K | ﹤0.01% | 3256 |
|
|
2020
Q4 | $1.29M | Buy |
58,672
+2,911
| +5% | +$60.6K | ﹤0.01% | 3102 |
|
|
2020
Q3 | $1.16M | Sell |
55,761
-197
| -0.4% | -$5.12K | ﹤0.01% | 3035 |
|
|
2020
Q2 | $2.02M | Buy |
55,958
+26,461
| +90% | +$1.11M | ﹤0.01% | 2666 |
|
|
2020
Q1 | $964K | Buy |
29,497
+7,095
| +32% | +$287K | ﹤0.01% | 3011 |
|
|
2019
Q4 | $611K | Buy |
22,402
+1,780
| +9% | +$30.5K | ﹤0.01% | 3483 |
|
|
2019
Q3 | $227K | Sell |
20,622
-196
| -0.9% | -$1.85K | ﹤0.01% | 3875 |
|
|
2019
Q2 | $172K | Buy |
+20,818
| New | +$197K | ﹤0.01% | 3950 |
|
Bank of New York Mellon's APLT Position: Q1 2026 in Review
Bank of New York Mellon sold out of Applied Therapeutics (APLT) in Q1 2026, closing a stake of 253,575 shares — an estimated $25.4K sold.
Bank of New York Mellon first reported a position in APLT in Q2 2019 and held it in 20 quarters. The position peaked at $2.09M in Q3 2024. 0 funds tracked by Wall St. Rank hold APLT as of Q1 2026.
- Bank of New York Mellon reported no remaining Applied Therapeutics position as of Q1 2026 after selling out during the quarter.
- Bank of New York Mellon sold 253,575 Applied Therapeutics shares in Q1 2026, an estimated $25.4K.
- Bank of New York Mellon first reported a position in Applied Therapeutics in Q2 2019 and held it in 20 quarters.
- Bank of New York Mellon's Applied Therapeutics position peaked at $2.09M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2026.
Based on Bank of New York Mellon's 13F filing for Q1 2026, filed 5 May 2026.